ArticleFrontiers in oncology2025
Assessment of cardiac radiation dose in the Co-60 prone-based stereotactic partial breast irradiation using distance metrics.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose/objectives: The GammaPod™ (GP) system, a contemporary platform dedicated to breast cancer (BC) radiotherapy, facilitates the delivery of accelerated partial breast irradiation (APBI) via the Co-60 prone-based stereotactic partial breast irradiation (CP-sPBI) technique. The precise CP-sPBI configuration permits reduced planning target volume (PTV) margins compared to other APBI techniques, creating an increased separation between PTV and organs at risk (OARs). This study explores the variability of heart-to-PTV distance and its effects on cardiac dosimetry. Materials/methods: An APBI database of 102 consecutive patients treated with CP-sPBI between March 2019 and February 2023 was queried for retrospective analysis. Statistical analyses were performed to evaluate the mean and maximum (max) heart and left anterior descending artery (LAD) doses based on two parameters: 1) D-H, the minimum distance between the heart and the lumpectomy cavity PTV, and 2) D-LAD, the minimum distance between the LAD and the lumpectomy cavity PTV. The median values of D-H and D-LAD, measured on either axial or sagittal planes, were employed to categorize patients based on cardiac dose levels. Results: The analysis revealed a statistically significant difference in the mean and max heart dose between patients with left-sided and right-sided breast cancer. Specifically, in left-sided breast cancer patients, median D-H and D-LAD cutoffs were identified as 2.67 and 3.22 cm, respectively. Patients with D-H less than 2.67 cm exhibited significantly higher mean (1.77 vs. 0.75 Gy; p < 0.01) and max heart doses (15.21 vs. 4.38 Gy; p < 0.01) compared to those with D-H greater than or equal to 2.67 cm. Similarly, lower D-LAD values (<3.22 cm) demonstrated a statistically significant association with increased arterial dose compared to higher D-LAD values (≥3.22 cm). Conclusions: Leveraging its sharp dose fall-off characteristic, the GP treatment delivery system facilitates the delivery of five-fraction APBI while maintaining acceptable cardiac dosimetry parameters. This is particularly advantageous for tumors situated further from the heart because heart doses dissipate with distance. The estimates of heart dose based on the distance to the heart and LAD from PTV have the potential to serve as a valuable tool for clinicians, aiding in more refined risk evaluation and patient selection for CP-sPBI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.